

# **Final Contract Year (CY) 2020 Marketing Guidance for New York’s Fully Integrated Duals Advantage for Individuals with Intellectual and Developmental Disabilities (FIDA-IDD) Medicare-Medicaid Plan**

**Issued: August 21, 2019**

## **Table of Contents**

Introduction .....	3
Use of Independent Agents and Brokers .....	3
Compliance with Section 1557 of the Affordable Care Act of 2010 .....	3
Formulary and Formulary Change Notice Requirements .....	3
Annual Marketing Plan .....	4
Section 10 - Introduction .....	4
Section 20 - Communications and Marketing Definitions .....	5
Section 30.2 - Standardization of Plan Name Type .....	5
Section 30.3 - Non-English Speaking Population .....	6
Section 40.2 - Marketing Through Unsolicited Contacts .....	6
Section 40.4 - Nominal Gifts .....	7
Section 40.6 - Marketing Star Ratings .....	7
Section 40.6.1 - Marketing Plans/Part D Sponsors with an Overall 5-Star Rating .....	7
Section 40.8 - Marketing of Rewards and Incentives Programs .....	7
Section 50.2 - Marketing/Sales Events .....	7
Section 50.3 - Personal/Individual Marketing Appointments .....	7
Section 60.1 - Provider-Initiated Activities .....	8
Section 60.4 - Plan/Part D sponsor Activities in the Healthcare Setting .....	8
Section 60.4.1 - Special Guidance for Plans/Part D Sponsors Serving Long-Term Care Facility Residents .....	8
Section 70.1.2 - Documents to be Posted on Website .....	8
Section 70.1.3 - Required Content .....	8
Section 80.1 – Customer Service Call Center Requirements and Standards .....	9
Section 80.1.1 - Customer Service Call Center Hours of Operations .....	9

Section 80.2 - Hours of Operation for Telephone Lines Solely Designated For Sales and Enrollment .....	9
Section 80.3 - Informational Scripts .....	9
Section 80.4 - Telesales and Enrollment Scripts .....	10
Section 80.7 - Activities That Do Not Require the Use of State-Licensed Marketing Representatives .....	10
Section 90 - Tracking, Submission, and Review Process.....	10
Section 90.1 - Material Identification .....	10
Section 90.1.1 - Materials Subject to Submission.....	10
Section 90.4 - Submission of Websites and Webpages for Review .....	11
Section 90.5 - Submission of Multi-Plan Materials.....	11
Section 90.6 - Status of HPMS Material .....	11
Section 90.7 - Resubmitting Previously Disapproved Pieces .....	11
Section 90.8 - File & Use Process .....	11
Section 100 - Required Materials.....	12
Section 100.4 - List of Required Materials .....	12
Table 1. Required Materials for New Participants .....	25
Section 110 - Agent/Broker Activities, Oversight, and Compensation Requirements.....	26
Appendix 2 - Disclaimers .....	26
Table 2. State-specific MMP Disclaimers .....	27
Appendix 3 - Pre-Enrollment Checklist .....	28
Appendix 7 - Use of Medicare Mark for Part D Sponsors .....	28

## **Introduction**

All Medicare Advantage-Prescription Drug (MA-PD) plan sponsor requirements in the Contract Year (CY) 2019 Medicare Communications and Marketing Guidelines (MCMG), posted at <http://www.cms.gov/Medicare/Health-Plans/ManagedCareMarketing/FinalPartCMarketingGuidelines.html>, and the August 6, 2019, Health Plan Management System (HPMS) guidance memorandum, “Medicare Communications and Marketing Guidelines,” apply to the Medicare-Medicaid Plan (MMP) participating in the New York capitated financial alignment model demonstration – also referred to as the Fully-Integrated Duals Advantage for individuals with Intellectual and Developmental Disabilities (FIDA-IDD) – except as noted or modified in this guidance document. The FIDA-IDD Plan is also required to follow all applicable New York State and federal regulations regarding marketing, including 18 CRR-NY 360-10.9 and 42 CFR 438.104.<sup>1</sup> For purposes of this document, we refer to the MMP operating in FIDA-IDD as the FIDA-IDD Plan, though we note that CMS uses the term MMP to refer to all plans in all states participating in capitated financial alignment model demonstrations. We also clarify that the FIDA-IDD Plan may not distribute any marketing materials that require state approval without first obtaining state approval.

This guidance document provides information only about those sections of the MCMG that are not applicable or that are different for the FIDA-IDD Plan in New York; therefore, this guidance document should be considered an addendum to the CY 2019 MCMG. This FIDA-IDD Plan guidance is applicable to all marketing done for CY 2020 benefits.

## **Use of Independent Agents and Brokers**

We clarify that all requirements applicable to independent agents/brokers throughout the MCMG are inapplicable to the FIDA-IDD Plan in New York because the use of independent agents/brokers is not permitted, and all FIDA-IDD Plan enrollment transactions must be processed by New York’s enrollment broker.

## **Compliance with Section 1557 of the Affordable Care Act of 2010**

The FIDA-IDD Plan is subject to the disclosure requirements under Section 1557 of the Affordable Care Act. For more information, the FIDA-IDD Plan should refer to <https://www.hhs.gov/civil-rights/for-individuals/section-1557/>.

## **Formulary and Formulary Change Notice Requirements**

The New York FIDA-IDD Plan should refer to the November 1, 2018, HPMS guidance memorandum, “Part D Communication Materials,” for guidance on formulary and formulary change notice requirements. As noted in that memorandum, additional updates to reflect changes related to 42 CFR 423.120(b)(5), regarding notice of mid-year formulary changes and changes to the definition of an approved month’s supply, will be incorporated into the Medicare Prescription Drug Benefit Manual in a future release. In addition, we note that the New York FIDA-IDD Plan is required to adhere to all new regulatory provisions and requirements.

---

<sup>1</sup> Note that any requirements for Special Needs Plans (SNPs), Private Fee-for-Service (PFFS) plans, Preferred Provider Organizations (PPOs), and Section 1876 Cost-Based Plans (cost plans) in the MCMG do not apply unless specifically noted in this guidance.

The requirements of the November 1, 2018, HPMS guidance memorandum apply with the following modifications:

- Formulary change notices must be sent for any negative formulary change (as described in Section 30.3.3, “Midyear Formulary Changes,” and Section 30.3.4, “Provision of Notice Regarding Formulary Changes,” of Chapter 6 of the Prescription Drug Benefit Manual), regardless of whether or not the negative formulary change applies to an item covered under Medicare or Medicaid, or as an additional drug benefit under the Plan.
- Formulary change notices applicable to all formulary changes (not just Part D drug changes) must be maintained on the New York FIDA-IDD Plan website.

### **Annual Marketing Plan**

The FIDA-IDD Plan is required to submit an annual marketing plan to the state for review and approval. More detail about this requirement is provided in section 10 of this document.

Following are the New York FIDA-IDD Plan-specific modifications to the MCMG for CY 2020.

### **Section 10 - Introduction**

The FIDA-IDD Plan must submit a plan of FIDA-IDD Plan marketing activities to the state that sets forth the terms and conditions and proposed activities of the FIDA-IDD Plan dedicated staff during the contract period. The following must be included in the marketing plan:

- A description of materials and formats to be used;
- Distribution methods;
- Primary types of marketing locations (such as, but not limited to, IDD program locations, other provider and community locations, health fairs, etc.); and
- A listing of the kinds of community service events the FIDA-IDD Plan anticipates sponsoring and/or participating in during which it will provide information and/or distribute FIDA-IDD Plan marketing materials.

An approved annual marketing plan must be on file with the state for its contracted service area prior to the FIDA-IDD Plan engaging in the FIDA-IDD Plan-specific marketing activities. The marketing plan may be submitted by September 30, 2020, or following the issuance of this guidance.

The marketing plan must include: (1) stated marketing goals and strategies; (2) a description of marketing activities, and the training, development and responsibilities of dedicated marketing staff; (3) a staffing plan, including personnel qualifications, training content and compensation methodology and levels; (4) a description of the FIDA-IDD Plan’s monitoring activities to ensure compliance with this section; and (5) identification of the primary marketing locations at which marketing will be conducted. The FIDA-IDD Plan must describe how it will meet the informational needs related to marketing for the physical and cultural diversity of its potential membership. This includes, but is not limited to, a description of the FIDA-IDD Plan’s non-English language provisions; interpreter services; and alternate communication mechanisms,

including sign language, braille, audio tapes, and/or use of teletypewriter (TTY) services. The FIDA-IDD Plan must describe measures for monitoring and enforcing compliance with these guidelines by its marketing representatives, including the prohibition of door-to-door solicitation and unsolicited telephonic or electronic contact; a description of the development of pre-enrollee mailing lists that maintains client confidentiality and honors the client's express request for direct contact by the FIDA-IDD Plan; and a description of the training, compensation, and supervision of its FIDA-IDD Plan dedicated marketing representatives.

We also note that providers may not provide mailing lists of their patients to the FIDA-IDD Plan. The FIDA-IDD Plan may also not require providers to distribute Plan-prepared communications to their patients.

## **Section 20 - Communications and Marketing Definitions**

MMPs are subject to marketing and beneficiary communications applicable to Medicare Advantage plans in 42 CFR 422 and 423, as well as those applicable to Medicaid managed care organizations in 42 CFR 438. CMS has developed a joint review process for MMP beneficiary materials under each Financial Alignment Initiative capitated model demonstration that combines state and CMS review requirements and parameters. Given these differences, CMS continues to consider all CY 2020 MMP materials to be marketing materials as defined prior to the implementation of CMS-4182-F.<sup>2</sup> As a result, this section of the MCMG and its subsections do not apply to MMPs. We provide additional detail about materials subject to HPMS submission in the guidance related to section 90.1.1 of the MCMG in this document. In addition, for any other references to communications throughout the MCMG, the previous definition of marketing materials applies.

## **Section 30.2 - Standardization of Plan Name Type**

As is the case for other Medicare health plans, the FIDA-IDD Plan is required to include the plan type in the plan's name using standard terminology consistent with the guidance provided in this section. CMS created the standardized plan type label "Medicare-Medicaid Plan" to refer generically to all plans participating in a capitated financial alignment model demonstration. The FIDA-IDD Plan must use the "Medicare-Medicaid Plan" plan type terminology following its plan name at least once on the front page or beginning of each marketing piece, excluding envelopes, consistent with the requirements of section 30.2 of the MCMG. In addition, New York requires the FIDA-IDD Plan to use the term "Fully-Integrated Duals Advantage for individuals with Intellectual and Developmental Disabilities" (FIDA-IDD) Plan to refer to itself. Thus, we clarify that the FIDA-IDD Plan must only use the CMS standardized plan type "(Medicare-Medicaid Plan)" following its plan name once in its materials but can then use the FIDA-IDD Plan terminology thereafter.

In addition, the state also expects the FIDA-IDD Plan to use the term FIDA-IDD in its plan name, as entered in HPMS and included in its marketing materials. For example, the FIDA-IDD Plan would use "Acme Duals FIDA-IDD Plan" as its plan marketing name in all participant materials.

---

<sup>2</sup> "Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE program," which may be found in the Federal Register published April 16, 2018 (see <https://www.federalregister.gov/documents/2018/04/16/2018-07179/medicare-program-contract-year-2019-policy-and-technical-changes-to-the-medicare-advantage-medicare>).

### **Section 30.3 - Non-English Speaking Population**

The requirements of section 30.3 of the MCMG apply with the modifications and clarifications included in this section. The standard articulated in this section for translation of marketing materials into non-English languages will be superseded to the extent that New York's standard for translation of marketing materials is more stringent. The New York translation standard - which requires translation of materials into a language that is the primary language of at least five percent (5%) of the FIDA-IDD Plan's enrolled population or fifty (50) participants, whichever is less - exceeds the Medicare standard for translation in the New York FIDA-IDD Plan service areas. Guidance on the translation requirements for all plans, including the FIDA-IDD Plan, is released via HPMS annually each fall. Required languages for translation for the FIDA-IDD Plan are also updated annually, as needed, in the HPMS Marketing Module.

At a minimum, for CY 2020, it is our expectation that the FIDA-IDD Plan will continue to meet the Medicare standard for translation of required marketing materials into Spanish in all service areas. CMS and the state have designated materials that are vital and, therefore, must be translated into the non-English languages specified in this section.<sup>3</sup> This information is located in section 100.4 of this document.

In addition, the FIDA-IDD Plan must translate ad hoc enrollee communication materials regarding payments and reimbursements in accordance with the standard described above. We note that ad hoc enrollee communication materials are not considered marketing materials and are not submitted in HPMS for marketing review. The process should include how the MMP will keep a record of the member's information and utilize it as an ongoing standing request so the member doesn't need to make a separate request for each material and how a member can change a standing request for preferred language and/or format.

The FIDA-IDD Plan must have a process to simply describe how they will request a participant's preferred language and/or format for receiving the materials identified in this section and will keep the information as a standing request for future mailings and communications. The FIDA-IDD Plan must also describe how a participant can change a standing request for preferred language and/or format. Standing requests pertain to alternate formats and all non-English languages identified in this section and in the HPMS Marketing Module.

For additional information regarding notice and tagline requirements, refer to Appendix A and Appendix B to Part 92 of Section 1557 of the Patient Protection and Affordable Care Act.

### **Section 40.2 - Marketing Through Unsolicited Contacts**

Section 40.2 of the MCMG provides examples of unsolicited direct contact with current and prospective participants. We reiterate that marketing via conventional mail and other print media (e.g., advertisements, direct mail) is not considered unsolicited contact and is, therefore, permissible.

---

<sup>3</sup> CMS makes available Spanish translations of the New York FIDA-IDD Plan Summary of Benefits (SB), Formulary (List of Covered Drugs), Provider and Pharmacy Network Directory, and ANOC/EOC (Participant Handbook). These are posted at <https://www.cms.gov/Medicare-Medicaid-Coordination/Medicare-and-Medicaid-Coordination/Medicare-Medicaid-Coordination-Office/FinancialAlignmentInitiative/MMPInformationandGuidance/MMPMarketingInformationandResources.html>.

We clarify that, under the MCMG, the FIDA-IDD plan is already permitted to send direct mail about the FIDA-IDD plan to participants who have opted out.

#### **Section 40.4 - Nominal Gifts**

Under the FIDA-IDD demonstration, the FIDA-IDD Plan may not offer financial or other incentives of any kind to induce potential FIDA-IDD plan participants to enroll with the FIDA-IDD plan or to refer a friend, neighbor, or other person to enroll with the plan. This includes nominal gifts provided at FIDA-IDD plan-targeted events. However, nominal gifts may be offered to potential FIDA-IDD plan participants.

Nominal gifts must be offered consistent with the guidance in section 40.4 of the MCMG.

#### **Section 40.6 - Marketing Star Ratings**

Because MMCO is in the process of developing a Star Ratings system for MMP performance, the FIDA-IDD Plan is not subject to the Star Ratings requirements in the MCMG. Therefore, this section does not apply to the FIDA-IDD Plan.

##### **Section 40.6.1 - Marketing Plans/Part D Sponsors with an Overall 5-Star Rating**

Because MMCO is in the process of developing a Star Ratings system for MMP performance, the FIDA-IDD Plan is not subject to the Star Ratings requirements in the MCMG. Therefore, this section does not apply to the FIDA-IDD Plan.

#### **Section 40.8 - Marketing of Rewards and Incentives Programs**

The FIDA-IDD Plan may market rewards and incentives to current FIDA-IDD Plan participants, as provided in section 40.8 of the MCMG. Any rewards and incentives programs must be consistent with section 100 of Chapter 4 of the Medicare Managed Care Manual.

#### **Section 50.2 - Marketing/Sales Events**

In addition to requirements in this section of the MCMG, the FIDA-IDD Plan must convene all educational and marketing events at sites within the plan's contracted service area that are physically accessible to all participants or potential FIDA-IDD Plan participants, including individuals with disabilities and individuals using public transportation.

#### **Section 50.3 - Personal/Individual Marketing Appointments**

We clarify that home and other one-on-one visits by non-sales plan employees for purposes related to care coordination are not considered individual marketing appointments. We note that such non-sales plan employees should never conduct marketing activity, as defined in section 20 of this guidance, but we clarify that they may provide factual information about the FIDA-IDD Plan and its benefits if the FIDA-IDD participant requests it in the course of care coordination activities.

## **Section 60.1 - Provider-Initiated Activities**

We clarify that the guidance in this section referring patients to other sources of information such as the “State Medicaid office” also applies to materials produced and/or distributed by New York’s enrollment broker.

## **Section 60.4 - Plan/Part D sponsor Activities in the Healthcare Setting**

In addition to the requirements of this section, we clarify that staff in health care settings such as, but not limited to, long-term care facilities, day care settings, and chronic and psychiatric hospitals for FIDA-IDD Plan-eligible individuals (post-stabilization) may provide residents meeting FIDA-IDD Plan eligibility criteria with an explanatory brochure about the FIDA-IDD Plan.

### **Section 60.4.1 - Special Guidance for Plans/Part D Sponsors Serving Long-Term Care Facility Residents**

In addition to the requirements of this section, we clarify that staff in health care settings such as, but not limited to, long-term care facilities, day care settings, and chronic and psychiatric hospitals for FIDA-IDD Plan-eligible individuals (post-stabilization) may provide residents meeting FIDA-IDD Plan eligibility criteria with an explanatory brochure about the FIDA-IDD Plan.

## **Section 70.1.2 - Documents to be Posted on Website**

The requirements of this section apply with the following modifications:

- The FIDA-IDD Plan is not be required to post the Low Income Subsidy (LIS) Premium Summary Chart, as this document is not applicable to MMPs.
- Because MMCO is in the process of developing a Star Ratings system for MMP performance, the FIDA-IDD Plan is not subject to the Star Ratings requirements in the MCMG. Therefore, the FIDA-IDD Plan is not required to post a CMS plan ratings document on its website.

## **Section 70.1.3 - Required Content**

In addition to the requirements outlined in this section, the FIDA-IDD Plan must also include on its website a direct link to New York’s enrollment broker. The FIDA-IDD Plan must also include information on the potential for contract termination (as required under 42 CFR 422.111(f)(4)), and information that materials are published in alternate formats (e.g., large print, braille, audio). As provided in section 70.1.1 of the MCMG, plan websites must be 508 compliant, and the FIDA-IDD Plan must attest that it complies with all applicable requirements when it submits its website for review in HPMS.

The FIDA-IDD Plan must also include a disclaimer, as provided in Appendix 2 of this guidance, on all marketing materials and on its website specifying the availability of the Participant Ombudsman to provide participants with free assistance in handling any issues related to accessing services. The FIDA-IDD Plan must include the toll-free number and the website for the Participant Ombudsman.



## **Section 80.1 – Customer Service Call Center Requirements and Standards**

We clarify that hold time messages that include marketing content must be submitted in HPMS, and the FIDA-IDD Plan must use marketing material code 16759 for this purpose. All other guidance in section 80.1 of the MCMG applies to MMPs.

### **Section 80.1.1 - Customer Service Call Center Hours of Operations**

We clarify that the FIDA-IDD Plan must operate a toll-free call center during usual business hours. In light of the scope and nature of the services and benefits provided by MMPs, CMS interprets usual business hours for customer service call centers for both current and prospective FIDA-IDD Plan participants as meaning at least the following: seven (7) days a week, at least from 8 a.m. to 8 p.m. ET, except as provided below. Customer service call center hours and days must be the same for all individuals regardless of whether they speak English, a non-English language, or use assistive devices for communication.

During this time period, current and prospective FIDA-IDD Plan participants must be able to speak with a live customer service representative. The FIDA-IDD Plan may use alternative technologies on Saturdays, Sundays, and federal and/or state holidays (except New Year's Day) in lieu of having live customer service representatives. For example, the FIDA-IDD Plan may use an interactive voice response (IVR) system or similar technologies to provide the required information listed in section 80.1 of the MCMG, and/or allow a participant to leave a message in a voice mail box. A customer service representative must then return the call in a timely manner, no more than one (1) business day later. All other guidance in section 80.1.1 of the MCMG applies to the FIDA-IDD Plan.

### **Section 80.2 - Hours of Operation for Telephone Lines Solely Designated For Sales and Enrollment**

Since the FIDA-IDD Plan is not allowed to market directly to individual potential enrollees and all enrollments into the Plan are submitted by the state's enrollment broker, this section does not apply.

### **Section 80.3 - Informational Scripts**

We clarify that informational calls to plan call centers that become marketing discussions, per the definition of marketing in section 20 of this guidance, may be conducted by plan staff provided such staff complies with the licensure requirements for marketing activity in section 110 of this guidance and the MCMG. Calls that become enrollment requests must be transferred to New York's enrollment broker.

Prior to transferring an informational call to New York's enrollment broker, the participant must be informed he/she is being transferred. The FIDA-IDD Plan representative may remain on the line during the call to New York's enrollment broker for enrollment calls.

The FIDA-IDD Plan should refer to section 80.7 of this guidance, as well as section 80.7 of the MCMG, for clarification of the types of activities conducted by a plan customer service representative that do not require the use of state-licensed marketing representatives. The FIDA-IDD Plan must use a state-licensed (and, when required, appointed) marketing agent for any activity that meets the definition of marketing in section 20 of this guidance.

## **Section 80.4 - Telesales and Enrollment Scripts**

Telesales scripts are considered marketing and must be submitted to CMS as outlined in section 90 of this guidance. The remainder of the guidance in this section on enrollment scripts does not apply to the FIDA-IDD Plan because enrollment requests must be transferred to New York's enrollment broker.

## **Section 80.7 - Activities That Do Not Require the Use of State-Licensed Marketing Representatives**

Consistent with section 80.7 of the MCMG, we clarify that, in order to provide more than factual information, FIDA-IDD Plan outbound callers must be state-licensed (and, when required, appointed) marketing agents. The FIDA-IDD Plan must use state-licensed (and, when required, appointed) marketing agents for any activity that meets the definition of marketing in section 20 of this guidance.

## **Section 90 - Tracking, Submission, and Review Process**

Any references in this section of the MCMG, and in all subsections thereunder, to CMS in its role in reviewing marketing materials are also references to the state for purposes of FIDA-IDD Plan marketing material review.

### **Section 90.1 - Material Identification**

The second paragraph of this section of the MCMG is modified as follows for the FIDA-IDD Plan:

The material ID is made up of two (2) parts: (1) MMP contract number, (i.e., H number) followed by an underscore; and (2) any series of alphanumeric characters chosen at the discretion of the FIDA-IDD Plan. Use of the material ID on marketing materials must be immediately followed by the status of either approved or accepted (e.g., H1234\_drugx38 Approved). Note that the FIDA-IDD Plan should include an approved status only after the material is approved and not when submitting the material for review.

In addition, when a third party, such as a pharmacy benefit manager (PBM), creates and distributes member-specific materials on behalf of multiple organizations, it is not acceptable to use the material ID for another organization for materials the third party provides to MMP enrollees. The material must be submitted in HPMS using a separate material ID number for the MMP, and that material ID number must be included on the material. The remainder of section 90.1 of the MCMG applies to the FIDA-IDD Plan, including the requirement that non-English and alternate format materials based on previously created materials may have the same material ID as the material on which they are based.

### **Section 90.1.1 - Materials Subject to Submission**

CMS has developed a joint review process for MMP beneficiary materials under each Financial Alignment Initiative capitated model demonstration that combines state and CMS review requirements and parameters. Given these differences, CMS will continue to consider all CY

2020 FIDA-IDD Plan materials to be marketing materials as defined prior to the implementation of CMS-4182-F in CY 2019.<sup>4</sup>

#### **Section 90.4 - Submission of Websites and Webpages for Review**

The requirements of this section apply without modification. We note, however, that the FIDA-IDD Plan should use state-specific MMP website codes. For more information about website codes, the FIDA-IDD Plan should consult the Marketing Code Lookup functionality in the HPMS Marketing Module.

#### **Section 90.5 - Submission of Multi-Plan Materials**

This section does not apply to the FIDA-IDD Plan.

#### **Section 90.6 - Status of HPMS Material**

We clarify that, for purposes of FIDA-IDD Plan materials, there is no “deeming” of materials requiring either a dual review by CMS and the state or a one-sided state review, and materials remain in a “pending” status until the state and CMS reviewer dispositions match. Materials in a “pending” status are not approved for use in the market. However, CMS and state marketing reviewers have standard operating procedures for ensuring materials are reviewed in a timely manner and differences in dispositions are resolved expeditiously. Materials that require a CMS-only review deem after the respective ten (10) or forty-five (45) day review period. The FIDA-IDD Plan may obtain more information about the specific review parameters and timeframes for marketing materials under the New York FIDA-IDD capitated financial alignment model demonstration in the Marketing Code Lookup functionality in the HPMS Marketing Module.

In addition to the guidance in this section, if the FIDA-IDD Plan submits modifications to a previously approved marketing material, it must submit a cover document that precisely lists all proposed wording changes to the previously approved marketing material. This will expedite the review and approval process.

We also note that the “non-marketing” status is not available for joint review process marketing codes in HPMS for CY 2020. All other guidance in this section of the MCMG applies.

#### **Section 90.7 - Resubmitting Previously Disapproved Pieces**

In addition to the requirements of this section, and in order to expedite the re-review and approval process, if the FIDA-IDD Plan resubmits previously disapproved pieces, it must submit a cover document that precisely lists all proposed wording changes to the previously disapproved materials.

#### **Section 90.8 - File & Use Process**

We clarify that the File & Use certification for the FIDA-IDD Plan is included in the three-way contract. All other guidance in section 90.8 of the MCMG applies.

---

<sup>4</sup> “Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE program,” which may be found in the Federal Register published April 16, 2018 (see <https://www.federalregister.gov/documents/2018/04/16/2018-07179/medicare-program-contract-year-2019-policy-and-technical-changes-to-the-medicare-advantage-medicare>).

## **Section 100 - Required Materials**

We clarify that CMS will continue to consider all CY 2020 MMP materials to be marketing materials as defined prior to the implementation of CMS-4182-F.<sup>5</sup> As a result, all marketing materials must be submitted in HPMS. All other portions of this section apply to MMPs.

### **Section 100.4 - List of Required Materials**

This section is replaced with the following revised guidance

#### **Section 100.4 - List of Required Materials**

42 CFR 417, 422, 423, 438

##### **Model Materials**

We clarify that marketing documents and marketing activities must reasonably accommodate individuals with physical or communications-related disabilities, including individuals with cognitive, learning, and psychiatric disabilities. Language related to this requirement is incorporated throughout this guidance.

We note that materials the FIDA-IDD Plan creates should take into account the reading level requirements established in the three-way contract. Available FIDA-IDD Plan-specific model materials reflect acceptable reading levels. Current Part D models are acceptable for use as currently provided, and the FIDA-IDD Plan must add required disclaimers in Appendix 2 of this guidance, as appropriate. Adding required FIDA-IDD Plan disclaimers to Part D models does not render the documents non-model when submitted for review or accepted as File & Use materials.

We refer the FIDA-IDD Plan to the following available model materials:

- FIDA-IDD Plan-specific model materials, including, but not limited to, an Annual Notice of Change (ANOC); a Summary of Benefits (SB); Evidence of Coverage (EOC) (Participant Handbook); Comprehensive Integrated Formulary (List of Covered Drugs); combined Provider and Pharmacy Directory; single Participant ID Card; the Integrated Coverage Determination Notice (ICDN) and other appeals and grievances notices; welcome letters and other plan-delegated enrollment notices; and FIDA-IDD specific Prescription Drug Explanation of Benefits (EOB), Transition Notice, Prescription Transfer Notice, and Excluded Provider Notice: <https://www.cms.gov/Medicare-Medicaid-Coordination/Medicare-and-Medicaid-Coordination/Medicare-Medicaid-Coordination-Office/FinancialAlignmentInitiative/MMPInformationandGuidance/MMPMarketingInformationandResources.htmlOffice/FinancialAlignmentInitiative/InformationandGuidanceforPlans.html>.
- Part D appeals and grievances models (including those in the Parts C & D Enrollee Grievances, Organization/Coverage Determinations and Appeals Guidance):

---

<sup>5</sup> “Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE program,” which may be found in the Federal Register published April 16, 2018 (see <https://www.federalregister.gov/documents/2018/04/16/2018-07179/medicare-program-contract-year-2019-policy-and-technical-changes-to-the-medicare-advantage-medicare>).

<https://www.cms.gov/Medicare/Appeals-and-Grievances/MedPrescriptDrugApplGriev/index.html> and <https://www.cms.gov/Medicare/Appeals-and-Grievances/MedPrescriptDrugApplGriev/PlanNoticesAndDocuments.html>, and <https://www.cms.gov/Medicare/Appeals-and-Grievances/MedPrescriptDrugApplGriev/Forms.html>.

- Part C appeals and grievances notices and models (including those in the Parts C & D Enrollee Grievances, Organization/Coverage Determinations and Appeals Guidance): <http://www.cms.gov/Medicare/Appeals-and-Grievances/MMCAG/Guidance.html> and <https://www.cms.gov/Medicare/Appeals-and-Grievances/MMCAG/Notices-and-Forms.html>.
- MMP-specific ANOC/EOC (Participant Handbook) errata model: <https://www.cms.gov/Medicare-Medicaid-Coordination/Medicare-and-Medicaid-Coordination/Medicare-Medicaid-Coordination-Office/FinancialAlignmentInitiative/MMPInformationandGuidance/MMPMarketingInformationandResources.htmlOffice/FinancialAlignmentInitiative/InformationandGuidanceforPlans.html>.

### Required Materials and Instructions for the FIDA-IDD Plan

Below is a list of required materials for the FIDA-IDD Plan. In addition, we provide high-level information for each material. Guidance (as noted) should be reviewed as applicable. Additionally, the FIDA-IDD Plan should consult the HPMS Marketing Code Lookup functionality for specific codes and instructions for uploading required materials.

The FIDA-IDD Plan may enclose additional benefit/plan operation materials with required materials, unless specifically prohibited in instructions or prohibited as noted below for each material. Additional materials must be distinct from required materials and must be related to the FIDA-IDD Plan in which the participant is enrolled.

Annual Notice of Changes (ANOC)	
<i>To Whom Required:</i>	Must be provided to current plan participants, including those with October 1, November 1, and December 1 effective dates.
<i>Timing:</i>	<ul style="list-style-type: none"> <li>• The FIDA-IDD Plan must send for participant receipt no later than September 30 of each year. (<b>Note:</b> The ANOC must be posted on the FIDA-IDD Plan website by October 15.)</li> <li>• Plan participants with October 1, November 1, and December 1 enrollment effective dates must receive the ANOC for the upcoming year by one (1) month after the effective date of enrollment but not later than December 15.</li> </ul>
<i>Method of Delivery:</i>	Hard copy, or electronically, if participant has opted into receiving electronic version as permitted in section 100.2.2 of the MCMG.
<i>HPMS Timing and Submission:</i>	<ul style="list-style-type: none"> <li>• Code 16708.</li> <li>• Must be submitted prior to mailing ANOCs.</li> </ul>
<i>Format Specification:</i>	<ul style="list-style-type: none"> <li>• NY FIDA-IDD MMP model required for current Contract Year.</li> <li>• Standardized model; a non-model document is not permitted.</li> </ul>

Annual Notice of Changes (ANOC)	
Guidance and Other Needed Information:	<ul style="list-style-type: none"> <li>Actual Mail Dates (AMDs) and number of recipients (not the number of ANOCs mailed) must be entered into HPMS within fifteen (15) calendar days of mailing. This includes mail dates for alternate materials. MMPs that mail in waves should enter the AMD for each wave. MMPs may enter up to ten (10) waves of mailings. For instructions on meeting this requirement, refer to the <i>Update AMD/Beneficiary Link/Function</i> section of the Marketing Review Users Guide in HPMS.</li> <li><b>Note:</b> For a single mailing to multiple recipients, as allowed under section 100.1 of the MCMG, the MMP should enter an AMD that reflects the number of recipients, not the number of ANOC/EOCs (Participant Handbooks), mailed.</li> <li>The plan may include the following with the ANOC: <ul style="list-style-type: none"> <li>Summary of Benefits (SB)</li> <li>Provider and Pharmacy Directory</li> <li>EOC (Participant Handbook)</li> <li>Formulary (List of Covered Drugs)</li> <li>Notification of Electronic Documents</li> <li>No additional plan communications unless otherwise directed.</li> </ul> </li> </ul>
Translation Required:	Yes.

<b>ANOC and EOC (Participant Handbook) Errata</b>	
<i>To Whom Required:</i>	Must be provided when plan errors are found in the ANOC or EOC (Participant Handbook) and sent to current participants.
<i>Timing:</i>	Must send to participants immediately following CMS approval.
<i>Method of Delivery:</i>	Hard copy, or electronically, if participant has opted into receiving electronic version as permitted in section 100.2.2 of the MCMG.
<i>HPMS Timing and Submission:</i>	<ul style="list-style-type: none"> <li>• Code 16705 for ANOC; code 16758 for the EOC (Participant Handbook).</li> <li>• ANOC errata must be submitted by October 15.</li> <li>• EOC (Participant Handbook) errata must be submitted by November 15.</li> </ul>
<i>Format Specification:</i>	Standardized model; a non-model document is not permitted.
<i>Guidance and Other Needed Information:</i>	<p>The FIDA-IDD Plan must use an errata notice to notify participants of plan errors in their original documents. We clarify that errata notices should only be used to notify participants of plan errors in plan materials.</p> <p><b>Note:</b> Any mid-year changes, including, but not limited to, mid-year legislative benefit additions or removals and changes in enrollment policies, should be communicated to current participants consistent with the “Mid-Year Change Notification” guidance in this section. The HPMS errata submission process should not be used for mid-year changes to materials that are not due to plan error. Instead the plan should use the HPMS Marketing Module replacement function for these changes.</p>
<i>Translation Required:</i>	Yes.

<b>Coverage/Organization Determination, Discharge, Appeals and Grievance Notices</b>	
<i>To Whom Required:</i>	<ul style="list-style-type: none"> <li>• Must be provided to participants who have requested an appeal or have had an appeal requested on their behalf.</li> <li>• Grievances may be responded to electronically, orally, or in writing.</li> </ul>
<i>Timing:</i>	Provided to participants (generally by mail) on an ad hoc basis, based on required timeframes in three-way contract.
<i>Method of Delivery:</i>	Hard copy, or electronically, if participant has opted into receiving electronic version as permitted in section 100.2.2 of the MCMG.
<i>HPMS Timing and Submission:</i>	<ul style="list-style-type: none"> <li>• Code 16720 for NY MMP state-specific appeals notices.</li> <li>• Various codes for other CMS required notices. Refer to HPMS Marketing Code Lookup functionality for NY MMP codes.</li> </ul>
<i>Format Specification:</i>	<ul style="list-style-type: none"> <li>• NY FIDA-IDD MMP models - standardized model; a non-model document is not permitted.</li> <li>• Other CMS models - modifications permitted.</li> </ul>
<i>Guidance and Other Needed Information:</i>	Three-way contract, Parts C & D Enrollee Grievances, Organization/Coverage Determinations, and Appeals Guidance.
<i>Translation Required:</i>	Yes.

<b>Evidence of Coverage (EOC) / Participant Handbook</b>	
<i>To Whom Required:</i>	Must be provided to all plan participants.
<i>Timing:</i>	<ul style="list-style-type: none"> <li>• Must send to current plan participants for receipt by October 15 of each year. Must be posted on plan website by October 15 of each year.</li> <li>• Must send to participants who opt in to the FIDA-IDD Plan for receipt no later than eight (8) calendar days from receipt of CMS confirmation of enrollment or by last day of the month prior to the effective date, whichever is later.</li> <li>• New participants with an effective date of October 1, November 1, or December 1 should receive both an EOC (Participant Handbook) for the current contract year, as well as an EOC (Participant Handbook) document for the upcoming contract year. We clarify that, for these participants, the ANOC may be included in the EOC (Participant Handbook) or provided separately, as well as the Formulary (List of Covered Drugs) (or a distinct and separate notice alerting participants how to access or receive the Formulary), and the Provider and Pharmacy Directory (or a distinct and separate notice alerting participants how to access or receive the directory) for the upcoming year, must be received by one (1) month after the effective date of enrollment, but not later than December 15.</li> </ul>
<i>Method of Delivery:</i>	Hard copy EOC (Participant Handbook) or via Notification of Electronic Documents (consistent with section 100.2.1 of the MCMG) or electronically, if participant has opted into receiving electronic version as permitted in section 100.2.2 of the MCMG.
<i>HPMS Timing and Submission:</i>	<ul style="list-style-type: none"> <li>• Code 16707.</li> <li>• Submitted prior to October 15 of each year.</li> </ul>
<i>Format Specification:</i>	<ul style="list-style-type: none"> <li>• NY FIDA-IDD MMP model required for current Contract Year.</li> <li>• Standardized model; a non-model document is not permitted.</li> </ul>
<i>Guidance and Other Needed Information:</i>	No additional information.
<i>Translation Required:</i>	Yes.

<b>Excluded Provider Letter</b>	
<i>To Whom Required:</i>	Provided to participants when a sponsor has excluded a prescriber or pharmacy participating in the Medicare program based on an Office of Inspector General (OIG) exclusion.
<i>Timing:</i>	Provided to participants on an ad hoc basis.
<i>Method of Delivery:</i>	Hard copy, or electronically, if participant has opted into receiving electronic version as permitted in section 100.2.2 of the MCMG.
<i>HPMS Timing and Submission:</i>	Code 16735.
<i>Format Specification</i>	Model provided; modifications permitted.
<i>Guidance and Other Needed Information:</i>	<a href="https://oig.hhs.gov/fraud/exclusions.asp">https://oig.hhs.gov/fraud/exclusions.asp</a>
<i>Translation Required:</i>	Yes.



<b>Explanation of Benefits (EOB) – Part D</b>	
<i>To Whom Required:</i>	Must be provided anytime a participant utilizes their prescription drug benefit.
<i>Timing:</i>	Sent at the end of the month following the month when the benefit was utilized.
<i>Method of Delivery:</i>	Hard copy, or electronically, if participant has opted into receiving electronic version as permitted in section 100.2.2 of the MCMG.
<i>HPMS Timing and Submission:</i>	Code 16734.
<i>Format Specification:</i>	NY FIDA-IDD MMP Rx-only EOB model - standardized model; a non-model document is not permitted.
<i>Guidance and Other Needed Information:</i>	Three-way contract, Medicare Prescription Drug Benefit Manual Chapters 5 and 6, and HPMS code usage instructions.
<i>Translation Required:</i>	Yes.

<b>Formulary (List of Covered Drugs)</b>	
<i>To Whom Required:</i>	Must be provided to all plan participants.
<i>Timing:</i>	<ul style="list-style-type: none"> <li>• Must be sent to current plan participants for receipt by October 15 of each year. Must be posted on plan website by October 15 of each year.</li> <li>• Must send to participants who opt in to the FIDA-IDD Plan for receipt no later than 8 (eight) calendar days from receipt of CMS confirmation of enrollment or by last day of the month prior to the effective date, whichever is later.</li> </ul>
<i>Method of Delivery:</i>	Hard copy, or via Notification of Electronic Documents (consistent with section 100.2.1 of the MCMG) or electronically, if the participant has opted into receiving electronic version as permitted in section 100.2.2 of the MCMG.
<i>HPMS Timing and Submission:</i>	Code 16702.
<i>Format Specification:</i>	Standardized model; a non-model document is not permitted.
<i>Guidance and Other Needed Information:</i>	<ul style="list-style-type: none"> <li>• The FIDA-IDD Plan must make available a comprehensive integrated Formulary (List of Covered Drugs) that includes Medicare and Medicaid outpatient prescription drugs and pharmacy products provided under the FIDA-IDD Plan.</li> <li>• Over-the-Counter (OTC) items and/or supplemental benefits that are in excess of Medicaid requirements may not be included in this document.</li> <li>• The FIDA-IDD Plan is only permitted to make available a comprehensive, not abridged, Formulary (List of Covered Drugs).</li> </ul>
<i>Translation Required:</i>	Yes.

<b>Integrated Denial Notice</b>	
<i>To Whom Required:</i>	Any participant with an adverse benefit determination.
<i>Timing:</i>	Provided to participants (generally by mail) on an ad hoc basis, at least 15 (fifteen) business days in advance of any adverse benefit determination.
<i>Method of Delivery:</i>	Hard copy, or electronically, if participant has opted into receiving electronic version as permitted in section 100.2.2 of the MCMG.
<i>HPMS Timing and Submission:</i>	Code 16719.
<i>Format Specification:</i>	<ul style="list-style-type: none"> <li>• NY FIDA-IDD MMP model required for current Contract Year.</li> <li>• Standardized model; a non-model document is not permitted.</li> </ul>
<i>Guidance and Other Needed Information:</i>	Three-way contract.
<i>Translation Required:</i>	Yes.

<b>Mid-Year Change Notification to Enrollees</b>	
<i>To Whom Required:</i>	Must be provided to all applicable participants when there is a mid-year change in benefits, plan rules, formulary, provider network, or pharmacy network.
<i>Timing:</i>	Ad hoc, based on specific requirements for each issue.
<i>Method of Delivery:</i>	Hard copy, or electronically, if participant has opted into receiving electronic version as permitted in section 100.2.2 of the MCMG. If the mid-year change affects a document that the MMP has not sent to the participant in hard copy (e.g., the EOC (Participant Handbook) the MMP is not required to send a hard copy mid-year change notification.
<i>HPMS Timing and Submission:</i>	Various codes. Refer to HPMS Marketing Code Lookup functionality for NY MMP codes.
<i>Format Specification:</i>	Model not available; must include required content.
<i>Guidance and Other Needed Information:</i>	<ul style="list-style-type: none"> <li>• Information about non-renewals or service area reductions may not be released to the public, including current participants, until a model notice is received from CMS.</li> <li>• The FIDA-IDD Plan may elect to share Non-Renewal and Service Area Reduction (NR/SAR) information only with first tier, downstream, and related entities (FDRs) or anyone that the Medicare Advantage Organization (MAO) does business with (i.e., contracted providers).</li> <li>• Additional NR/SAR notice information can be found in the annual “Non-Renewal and Service Area Reduction Guidance and Enrollee Notification Models” HPMS memo.</li> <li>• If a non-model document is created, the document must contain all the elements in the model.</li> </ul>
<i>Translation Required:</i>	Yes.

<b>Non-Renewal and Termination Notices</b>	
<i>To Whom Required:</i>	Must be provided to each affected enrollee after MMP decides to non-renew or reduce its plan's service area or before the termination effective date.
<i>Timing:</i>	At least 90 days before the end of the current contract period.
<i>Method of Delivery:</i>	Notices must be hard copy and sent via U.S. mail. First class postage is recommended.
<i>HPMS Timing and Submission:</i>	Code 16711 for both notices
<i>Format Specification:</i>	NY FIDA IDD MMP Model required for current contract year. Modifications permitted per instructions
<i>Guidance and Other Needed Information:</i>	<ul style="list-style-type: none"> <li>Information about non-renewals or service area reductions may not be released to the public, including current enrollees, until notice is received from CMS and the state.</li> <li>MMPs may elect to share Non-Renewal and Service Area Reduction (NR/SAR) information only with first tier, downstream, and related entities (FDRs) or anyone that the MMP does business with (i.e., contracted providers).</li> <li>Additional NR/SAR notice information can be found in the annual "Non-Renewal and Service Area Reduction Guidance and Enrollee Notification Models" HPMS memo.</li> <li>For terminations, relevant notice requirements are provided in 42 CFR 422.506, 422.508, and 422.512.</li> </ul>
<i>Translation Required:</i>	Yes.

<b>Part D Transition Letter</b>	
<i>To Whom Required:</i>	Must be provided when a participant receives a transition fill for a non-formulary drug.
<i>Timing:</i>	Must be sent within three (3) business days of adjudication of temporary transition fill.
<i>Method of Delivery:</i>	Hard copy.
<i>HPMS Timing and Submission:</i>	Code 16738.
<i>Format Specification:</i>	Model provided; modifications permitted.
<i>Guidance and Other Needed Information:</i>	Medicare Prescription Drug Benefit Manual, Chapter 6, section 30.4.10.
<i>Translation Required:</i>	Yes.

<b>Participant ID Card</b>	
<i>To Whom Required:</i>	Must be provided to all plan participants.
<i>Timing:</i>	<ul style="list-style-type: none"> <li>• Must send to participants who opt in to the FIDA-IDD Plan for receipt no later than eight (8) calendar days from receipt of CMS confirmation of enrollment or by last day of the month prior to the effective date, whichever is later.</li> <li>• Must also be provided to all participants if information on existing card changes.</li> </ul>
<i>Method of Delivery:</i>	Must be provided in hard copy. In addition to the hard copy, the plan may also provide a digital version (e.g., app).
<i>HPMS Timing and Submission:</i>	Code 16710.
<i>Format Specification:</i>	Standardized model; a non-model document is not permitted.
<i>Guidance and Other Needed Information:</i>	The FIDA-IDD Plan must issue a single Participant ID Card meeting these requirements for all services offered under the plan. Separate pharmacy and health benefits ID cards are not permitted.
<i>Translation Required:</i>	No.

<b>Plan-Delegated Enrollment and Disenrollment Notices</b>	
<i>To Whom Required:</i>	Must be provided as outlined in National Enrollment/Disenrollment Guidance for States & MMPs.
<i>Timing:</i>	Varies; must follow required timeframes as outlined in National Enrollment/Disenrollment Guidance for States & MMPs.
<i>Method of Delivery:</i>	Hard copy, or electronically, if participant has opted into receiving electronic version as permitted in section 100.2.2 of the MCMG.
<i>HPMS Timing and Submission:</i>	Code 16747.
<i>Format Specification:</i>	<ul style="list-style-type: none"> <li>• NY FIDA-IDD MMP model required for current Contract Year.</li> <li>• Standardized model; a non-model document is not permitted.</li> </ul>
<i>Guidance and Other Needed Information:</i>	<ul style="list-style-type: none"> <li>• National Enrollment/Disenrollment Guidance for States &amp; MMPs.</li> <li>• NY FIDA-IDD Enrollment Guidance Appendix 5.</li> <li>• The FIDA-IDD Plan must use the Marketing Code Lookup functionality in the HPMS Marketing Module, along with the enrollment/disenrollment guidance to determine the most appropriate code for its submissions.</li> </ul>
<i>Translation Required:</i>	Yes.

<b>Prescription Transfer Letter</b>	
<i>To Whom Required:</i>	When a Part D sponsor requests permission from a participant to fill a prescription at a different network pharmacy than the one currently being used by the participant.
<i>Timing:</i>	Ad hoc.
<i>Method of Delivery:</i>	Hard copy.
<i>HPMS Timing and Submission:</i>	Code 16736.
<i>Format Specification:</i>	Model provided; modifications permitted.
<i>Guidance and Other Needed Information:</i>	The model notice should only be used when the transfer of the prescription is not initiated by the participant (or someone on his or her behalf).
<i>Translation Required:</i>	Yes.

<b>Provider and Pharmacy Directory</b>	
<i>To Whom Required:</i>	Must be provided to all current plan participants.
<i>Timing:</i>	<ul style="list-style-type: none"> <li>• Must be sent to current plan participants for receipt by October 15 of each year. Must be posted to plan website by October 15 of each year.</li> <li>• Must send to participants who opt in to the FIDA-IDD Plan for receipt no later than eight (8) calendar days from receipt of CMS confirmation of enrollment or by last day of the month prior to the effective date, whichever is later.</li> <li>• Must be provided to current participants upon request, within three (3) business days of the request.</li> <li>• Must update directory information any time they become aware of changes. All updates to the online Provider and Pharmacy Directory are expected to be completed within thirty (30) calendar days of receiving information. Updates to hard copy of the Provider and Pharmacy Directory must be completed within thirty (30) calendar days; however, a hard copy directory that includes separate updates via addenda is considered up-to-date.</li> </ul>
<i>Method of Delivery:</i>	Hard copy or via Notice of Electronic Documents (consistent with section 100.2.1 of the MCMG) or electronically, if participant has opted into receiving electronic version as permitted in section 100.2.2 of the MCMG.
<i>HPMS Timing and Submission:</i>	Code 16080.
<i>Format Specification:</i>	<ul style="list-style-type: none"> <li>• NY FIDA-IDD MMP model required for current Contract Year.</li> <li>• Standardized model; a non-model document is not permitted.</li> </ul>

<b>Provider and Pharmacy Directory</b>	
<i>Guidance and Other Needed Information:</i>	<ul style="list-style-type: none"> <li>• The FIDA-IDD Plan is required to make available a single combined Provider and Pharmacy Directory. Separate pharmacy and provider directories are not permitted. The FIDA-IDD Plan may print separate directories for primary care physicians (PCPs) and specialists provided both directories are made available to participants at the time of enrollment.</li> <li>• The single combined Provider and Pharmacy Directory must include all network providers and pharmacies, regardless of whether they provide Medicare, Medicaid, or additional benefits.</li> <li>• For an MMP with multi-county service areas, the combined Provider and Pharmacy Directory may be provided for all providers by county, provided the directory includes a disclaimer that the directory only includes providers in that particular county (or counties), that a complete directory is available on the plan's website, and that the participant may contact the plan's customer service call center to request assistance with locating providers in other counties or to request a complete hard copy Provider and Pharmacy Directory.</li> <li>• The NY FIDA-IDD Plan must submit directory updates and/or addenda pages in HPMS, and these documents are reviewed consistent with the parameters for the NY FIDA-IDD Plan Provider and Pharmacy Directory marketing code.</li> <li>• As applicable, refer to the language and guidelines issued in the August 16, 2018, HPMS memorandum, "Pharmacy Directories and Disclaimers" for the pharmacy portion of the combined directory.</li> </ul>
<i>Translation Required:</i>	Yes.

<b>Summary of Benefits (SB)</b>	
<i>To Whom Required:</i>	Optional with the ANOC and as requested for other Participants.
<i>Timing:</i>	Must be available by October 15 of each year but can be released as early as October 1 of each year. Must be posted on plan website by October 15 of each year.
<i>Method of Delivery:</i>	Hard copy.
<i>HPMS Timing and Submission:</i>	Code 16700. Submitted prior to October 15 of each year.
<i>Format Specification:</i>	<ul style="list-style-type: none"> <li>• NY FIDA-IDD Plan model required for current Contract Year.</li> <li>• Standardized model; a non-model document is not permitted.</li> </ul>
<i>Guidance and Other Needed Information:</i>	<ul style="list-style-type: none"> <li>• The SB must contain a concise description of the important aspects of enrolling in the plan, as well as the benefits offered under the plan, including applicable conditions and limitations and any other conditions associated with receipt or use of benefits.</li> <li>• Appendix 5 of the MCMG, Summary of Benefit Instructions, does not apply.</li> </ul>
<i>Translation Required:</i>	Yes.

<b>Welcome Letter</b>	
<i>To Whom Required:</i>	Must be provided to all new Plan participants.
<i>Timing:</i>	Must send to participants who opt in to the FIDA-IDD Plan for receipt no later than eight (8) calendar days from receipt of CMS confirmation of enrollment or by last day of the month prior to the effective date, whichever is later.
<i>Method of Delivery:</i>	Hard copy.
<i>HPMS Timing and Submission:</i>	Code 16701.
<i>Format Specification:</i>	NY FIDA-IDD Plan model required for Contract Year.
<i>Guidance and Other Needed Information:</i>	<ul style="list-style-type: none"> <li>• Must contain 4Rx information consistent with the model.</li> <li>• National Enrollment/Disenrollment Guidance for States &amp; MMPs section 30.5.1.</li> </ul>
<i>Translation Required:</i>	Yes.

### **Required Materials for New FIDA-IDD Plan participants**

The following table summarizes the required materials, and timing of receipt, for new FIDA-IDD Plan participants.



**Table 1. Required Materials for New Participants**

Enrollment Mechanism	Required Materials for New Participants	Timing of Participant Receipt
Opt in enrollment (with enrollment confirmation received more than eight (8) calendar days before the end of the month) <sup>6</sup>	<ul style="list-style-type: none"> <li>• Welcome letter</li> <li>• Formulary (List of Covered Drugs) (or a distinct and separate notice alerting participants how to access or receive the Formulary)</li> <li>• Provider and Pharmacy Directory (or a distinct and separate notice alerting participants how to access or receive the Directory)</li> <li>• Participant ID Card</li> <li>• EOC (Participant Handbook) (or a distinct and separate notice alerting participants how to access or receive the EOC (Participant Handbook))</li> </ul>	No later than the last day of the month prior to the effective date of enrollment.

<sup>6</sup> The FIDA-IDD Plan should refer to the date of the Daily Transaction Reply Report (DTRR) that has the notification to identify the start of the eight (8) calendar-day timeframe.

Enrollment Mechanism	Required Materials for New Participants	Timing of Participant Receipt
Opt in enrollment (with enrollment confirmation received less than eight (8) calendar days before the end of the month) <sup>7</sup>	<ul style="list-style-type: none"> <li>• Welcome letter</li> <li>• Formulary (List of Covered Drugs) (or a distinct and separate notice alerting participants how to access or receive the Formulary)</li> <li>• Provider and Pharmacy Directory (or a distinct and separate notice alerting participants how to access or receive the Directory)</li> <li>• Participant ID Card</li> <li>• EOC (Participant Handbook) (or a distinct and separate notice alerting participants how to access or receive the EOC (Participant Handbook))</li> </ul>	No later than eight (8) calendar days from receipt of the confirmation of enrollment.

## Section 110 - Agent/Broker Activities, Oversight, and Compensation Requirements

The provisions in this section of the MCMG and all its subsections applicable to independent agents/brokers do not apply to the FIDA-IDD Plan since the use of independent agents/brokers is not permitted. All FIDA-IDD Plan enrollments are processed by New York's enrollment broker. We clarify that CMS and NYSDOH do not regulate compensation of employed agents for the FIDA-IDD Plan.

We also clarify that the FIDA-IDD Plan staff conducting marketing activity of any kind, as defined in section 20 of this guidance, must be licensed in the state (and, when required, appointed) as an insurance broker/agent.

## Appendix 2 - Disclaimers

The disclaimer language in the following table replaces the language in Appendix 2 of the MCMG.

<sup>7</sup> The FIDA-IDD Plan should refer to the date of the Daily Transaction Reply Report (DTRR) that has the notification to identify the start of the eight (8) calendar-day timeframe.

**Table 2. State-specific MMP Disclaimers**

**Note:** Disclaimers are not required on the following material types: ID cards, call scripts, banners and banner-like ads, envelopes, outdoor advertising, text messages, and social media.

Disclaimer	Required MMP Disclaimer Language	MMP Disclaimer Instructions
Federal Contracting	<Plan's legal or marketing name> is a managed care plan that contracts with Medicare and the New York State Department of Health (Medicaid) to provide benefits to participants through the Fully Integrated Duals Advantage for Individuals with Intellectual and Developmental Disabilities (FIDA-IDD) Demonstration.	Required on materials except those specifically excluded above.
Benefits – “This is not a complete list...”	This is not a complete list. The benefit information is a brief summary, not a complete description of benefits. For more information contact the plan or read the <plan name> Participant Handbook.	Required on the SB and all materials with ten (10) or more benefits except the EOC (Participant Handbook).
Availability of Non-English Translations	ATTENTION: If you speak <language of disclaimer>, language assistance services, free of charge, are available to you. Call <Participant Services toll-free phone and TTY numbers, and days and hours of operation>. The call is free.	Required in applicable non-English languages on those model materials in section 100.4 for which the last row of the table indicates, “ <i>Translation required: Yes.</i> ”
Non-plan and Non-health Information	Neither Medicare nor New York Medicaid has reviewed or endorsed this information.	Required on non-plan and non-health related information once prior authorization from the Participant is granted to receive materials.

Disclaimer	Required MMP Disclaimer Language	MMP Disclaimer Instructions
Participant Ombudsman	The State of New York has created a Participant Ombudsman Program called the Independent Consumer Advocacy Network (ICAN) to provide participants free, confidential assistance on any services offered by <plan name>. ICAN may be reached toll-free at 1-844-614-8800 (TTY users call 711, then follow the prompts to dial 844-614-8800) or online at <a href="http://icannys.org">icannys.org</a> .	Required on all marketing materials (except radio ads) and required on the plan's website.

**Note:** For model materials, MMPs must continue to include disclaimers where they currently appear. For non-model materials, MMPs may include disclaimers as footnotes or incorporate them into the body of the material.

### **Appendix 3 - Pre-Enrollment Checklist**

This appendix does not apply to the FIDA-IDD Plan since all enrollments are submitted by New York's enrollment broker.

### **Appendix 7 - Use of Medicare Mark for Part D Sponsors**

We clarify that the FIDA-IDD Plan is required to sign a licensing agreement to use the official Medicare Mark as part of the three-way contract, rather than through the HPMS contracting module. All other guidance in Appendix 7 of the MCMG applies.